MedTrace Logo

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

NCT04586543 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2020-10-14

No results posted yet for this study

Summary

The objective of this clinical study is to evaluate the effectiveness and safety of selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy - among patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma.

Conditions

Interventions

DRUG

Selegiline

10 mg selegiline tablet per day

DRUG

Docetaxel

75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles

Sponsors & Collaborators

  • E-Group ICT Software Informatikai Zrt.

    collaborator UNKNOWN

  • László Mangel

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-18
Primary Completion
2025-02-01
Completion
2025-02-01

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04586543 on ClinicalTrials.gov